ATEMESBVLIBXCI-UHFFFAOYSA-N
C38H29F7N12 — CID 154975212
Data last refreshed: (MolForge compound catalog, from PubChem)
About ATEMESBVLIBXCI-UHFFFAOYSA-N
ATEMESBVLIBXCI-UHFFFAOYSA-N (PubChem CID 154975212) has the molecular formula C38H29F7N12 and a molecular weight of 786.72 g/mol. Its IUPAC name is 5-fluoro-2-(2-methylbenzimidazol-1-yl)-4-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine;2-(2-methylbenzimidazol-1-yl)-4-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine.
Molecular Properties
| Compound Name | ATEMESBVLIBXCI-UHFFFAOYSA-N |
|---|---|
| PubChem CID | 154975212 |
| Molecular Formula | C38H29F7N12 |
| Molecular Weight | 786.72 g/mol |
| Exact Mass | 786.25 |
| IUPAC Name | 5-fluoro-2-(2-methylbenzimidazol-1-yl)-4-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine;2-(2-methylbenzimidazol-1-yl)-4-N-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine |
| SMILES | Cc1nc2ccccc2n1-c1nc(N)c(F)c(Nc2ccc(C(F)(F)F)cc2)n1.Cc1nc2ccccc2n1-c1nc(N)cc(Nc2ccc(C(F)(F)F)cc2)n1 |
| InChI | InChI=1S/C19H14F4N6.C19H15F3N6/c1-10-25-13-4-2-3-5-14(13)29(10)18-27-16(24)15(20)17(28-18)26-12-8-6-11(7-9-12)19(21,22)23;1-11-24-14-4-2-3-5-15(14)28(11)18-26-16(23)10-17(27-18)25-13-8-6-12(7-9-13)19(20,21)22/h2-9H,1H3,(H3,24,26,27,28);2-10H,1H3,(H3,23,25,26,27) |
| InChIKey | ATEMESBVLIBXCI-UHFFFAOYSA-N |
| XLogP | 9.08 |
| TPSA | 163.30 Ų |
| H-Bond Donors | 4 |
| H-Bond Acceptors | 12 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 57 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 786.72 |
| LogP ≤ 5 | 9.08 |
| H-Bond Donors ≤ 5 | 4 |
| H-Bond Acceptors ≤ 10 | 12 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 154975212 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.